Key Takeaways
- • MAK Capital, holding a 7% stake in Evotec SE, is pushing for a spinoff and US listing of Just Biologics, the company's Seattle-based subsidiary, targeting a valuation exceeding €1 billion to unlock shareholder value.
- • Evotec's share price has collapsed 85% over five years and declined 17% since the start of 2025, leaving the German biotech company with a market capitalization of approximately €800 million, creating urgency for activist intervention.
- • MAK Capital criticizes the pace of Evotec's restructuring timeline, which delays meaningful margin improvement until 2027 or later, and is demanding accelerated cost reductions with measurable operational progress by the second half of 2026.
- • The activist investor has nominated Wolfgang Hofmann, a former Novartis and Fresenius executive, to replace supervisory board member Duncan McHale at the upcoming annual shareholder meeting, signaling deeper governance pressure.
Summary
Activist investor MAK Capital, founded by Michael A Kaufman, has launched a comprehensive campaign to reshape Evotec SE's strategy, leveraging a recently disclosed 7% stake to press for the spinoff and independent listing of the company's US-based subsidiary, Just Biologics. In a regulatory filing containing a letter to management, MAK argues that separating the Seattle-headquartered unit could achieve a valuation exceeding €1 billion, materially benefiting Evotec shareholders through an expanded investor base, capital for expansion, and enhanced talent recruitment capabilities.
The intervention reflects acute shareholder frustration with Evotec's operational trajectory and capital allocation. The German biotech company's share price has contracted approximately 85% over the past five years, with additional deterioration of 17% since the start of 2025, compressing market capitalization to roughly €800 million. This severe valuation compression underscores the urgency of activist demands for strategic action.
Beyond the spinoff proposal, MAK Capital has issued a direct challenge to management's restructuring timeline, contending that current plans delay meaningful margin improvement until 2027 or beyond—a delay the activist warns could erode competitive positioning. The fund is explicitly demanding accelerated cost reduction measures and measurable operational improvements starting in the second half of 2026, signaling impatience with incremental progress.
Governance changes accompany the operational demands. MAK has nominated Wolfgang Hofmann, bringing prior executive experience from Novartis and Fresenius, to replace Duncan McHale on the supervisory board at the upcoming annual shareholder meeting. This personnel proposal demonstrates the activist's intent to embed board-level influence over implementation and accountability.
Evotec has not yet publicly responded to MAK's intervention, leaving the company's formal stance on the spinoff proposal, restructuring acceleration, and board nomination unclear at this stage.
The intervention reflects acute shareholder frustration with Evotec's operational trajectory and capital allocation. The German biotech company's share price has contracted approximately 85% over the past five years, with additional deterioration of 17% since the start of 2025, compressing market capitalization to roughly €800 million. This severe valuation compression underscores the urgency of activist demands for strategic action.
Beyond the spinoff proposal, MAK Capital has issued a direct challenge to management's restructuring timeline, contending that current plans delay meaningful margin improvement until 2027 or beyond—a delay the activist warns could erode competitive positioning. The fund is explicitly demanding accelerated cost reduction measures and measurable operational improvements starting in the second half of 2026, signaling impatience with incremental progress.
Governance changes accompany the operational demands. MAK has nominated Wolfgang Hofmann, bringing prior executive experience from Novartis and Fresenius, to replace Duncan McHale on the supervisory board at the upcoming annual shareholder meeting. This personnel proposal demonstrates the activist's intent to embed board-level influence over implementation and accountability.
Evotec has not yet publicly responded to MAK's intervention, leaving the company's formal stance on the spinoff proposal, restructuring acceleration, and board nomination unclear at this stage.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.